Key insights
- Solesence is transitioning to a strategic supply-side innovation partner, aiming for higher enterprise value. Q1 revenue declined due to operational issues, but gross margins expanded. New technologies and service models are being launched. Management expects improved profitability with a 30% gross margin floor and double-digit EBITDA margins by year-end. Revenue is expected to normalize after hyper-growth.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management is transitioning the business model from a traditional Contract Development and Manufacturing Organization (CDMO) to a strategic supply-side innovation partner to capture higher enterprise value.
The 'Transform and Transcend' initiative was launched to align operational execution with the company's technology platforms following a period of rapid 50% compounded annual growth.
First-quarter revenue decline was attributed to soft On-Time and In-Full (OTIF) performance caused by internal process changes and misaligned material/componentry arrivals.
Gross margin expansion of 300 basis points was achieved through improved labor efficiency and the elimination of product quality-related waste seen in the prior year.
The company implemented a new shift structure and lean manufacturing training to address extended process changeovers and downtime that previously inflated labor costs.
Strategic positioning is being bolstered by the launch of proprietary technologies, Chromalum and WHSPR, aimed at the convergence of health, wellness, and beauty markets.
A new service model is being piloted through co-marketing activations with brand partners like Color Science and BloomAX to capture a greater share of the value chain.
Management reiterated a 30% floor for gross profit margins for the full year 2026 as operational improvements take hold.
The company expects to return to double-digit EBITDA margins by the end of the year, driven by labor efficiencies and six-figure annual savings from facility consolidation.
Revenue for 2026 is expected to reflect a 'normalized' environment following years of hyper-growth, with current shipped and open orders totaling $47 million.
Operational priorities for the remainder of the year include the implementation of Sales, Inventory, and Operations Planning (SIOP) to improve procurement and working capital discipline.
Future growth initiatives include leveraging new IP to expand into adjacent categories such as hair and scalp care.
The shift to a net loss of $0.8 million reflects intentional near-term investment in organizational realignment and infrastructure.
Inventory management remains a critical focus area as the company works to synchronize the receipt of raw materials with packaging componentry.
Facility consolidation is cited as a key driver for upcoming cost reductions, though specific timing of the full realization was not detailed beyond 'by the end of the year'.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management clarified that lower Q1 revenue was an execution issue (OTIF performance) rather than a lack of market interest or demand.
Kevin Cureton noted that with proper OTIF performance, Q1 revenue would have been in line with prior quarters.
Delays occurred because raw material formulations and packaging components were not consistently arriving at the same time.
Management reported substantial improvements in these processes as they exited Q1 and entered Q2.
The $47 million figure represents a combination of year-to-date shipped orders and current open orders (backlog) due for delivery within the year.
Management is currently evaluating whether this specific metric provides the most effective guidance for investors moving forward.